Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Starpharma Holdings Limited
About
  2. Companies
  3. Starpharma Holdings Limited
  4. Products
  5. Starpharma - Antibody Drug Conjugates

Starpharma - Antibody Drug Conjugates

SHARE

Starpharma’s DEP® technology provides enhanced therapeutic benefits to Antibody Drug Conjugates (ADCs) including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. The use of ADCs is an innovative and cutting-edge area in cancer therapy that continues to grow, and Starpharma has a number of partner programs in the area. Starpharma’s novel DEP® HER-2 Targeted ADC binds to the same target (HER-2) as the leading monoclonal antibody and ADC cancer therapies, Herceptin® and Kadcyla®, which had sales in excess of US$5 billion in 2021.

Most popular related searches
drug conjugate
cancer treatment
monoclonal antibody
therapeutic benefit
drug delivery
cancer treatment antibody
small molecule drug
small-molecule drug
therapeutic antibody
drug attached

Starpharma’s DEP® ADC’s provide many benefits over existing ADCs and can overcome many issues faced today by existing ADC approaches, including:

  • Greater homogeneity

  • Site specific attachment of drug conjugate

  • High affinity

  • The delivery of significantly higher payload levels than conventional ADCs

  • Overcome issues of payload solubility and aggregation.

Targeting

  • Flexibility in use of targeting molecule Ab; Ab fragment; Non-Ab ligand; Small molecule

DEP® drug conjugate

  • Dendrimer size easily scalable to deliver desired payload number (8, 16, 32...)
  • Can deliver any type of payload - cytotoxic or ultra-toxic

Site specific attachment

  • Precise and reproducible
  • Ability to attach multiple dendrimers - high Drug Antibody Ratio (DAR)